IP Library Granted Patent US 10,370,645
Granted Patent B2
US 10,370,645 · App. 15/173,316 · Granted Aug 6, 2019

Endocrine precursor cells, pancreatic hormone-expressing cells and methods of production

Inventors: Kevin A. D'Amour (San Diego, CA); Anne Bang (San Diego, CA); Emmanuel E. Baetge (Sulpice, CH)
Assignees: Emory University; Dana-Farber Cancer Institute, Inc.; Brigham and Women's Hopsital, Inc.; President and Fellows of Harvard College
C12N5/0676A61K35/39C12N5/0678C12N2500/38C12N2501/10C12N2501/105C12N2501/115C12N2501/119C12N2501/12C12N2501/15C12N2501/16C12N2501/33C12N2501/335C12N2501/385C12N2501/41C12N2501/415C12N2501/42C12N2501/58C12N2501/734C12N2501/999C12N2506/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,370,645
App. No.
15/173,316
Granted
Aug 6, 2019
Kind
B2
Abstract

Disclosed herein are cell cultures and enriched cell populations of endocrine precursor cells, immature pancreatic hormone-expressing cells and mature pancreatic hormone-expressing cells. Also disclosed herein are methods of producing such cell cultures and cell populations.

Claims (11)

1. An in vitro method of making a population of human pancreatic and duodenal homeobox (PDX1)-positive pancreatic endoderm, comprising:

a) obtaining a population of human definitive endoderm cells; and

b) contacting the population of human definitive endoderm cells from step (a) with a retinoid, thereby making the population of human PDX1-positive pancreatic endoderm.

2. The method of claim 1 , further comprising contacting the population of human definitive endoderm cells from step (a) with the gamma secretase inhibitor.

3. The method of claim 2 , wherein the gamma secretase inhibitor is N—[N-(3,5-Diflurophenaacetyl-L-alanyl)]-S-phenylglycine t-Butyl Ester (DAPT).

4. The method of claim 1 , further comprising transplanting the population of human PDX1-positive endoderm cells into a human host to mature into insulin secreting cells.

5. The method of claim 4 , wherein the insulin secreting cells form islet-like cell clusters.

6. The method of claim 5 , wherein the islet-like cell clusters comprise singly-positive insulin secreting cells.

7. The method of claim 1 , wherein the population of human PDX1-positive pancreatic endoderm cells expresses neurogenin (NGN3) and does not substantially express a marker selected from the group consisting of ghrelin, glucagon, insulin, and islet amyloid polypeptide (IAPP).

8. The method of claim 1 , further comprising contacting the population of human PDX1-positive pancreatic endoderm cells with a factor selected from the group consisting of nicotinamide (NIC), exendin 4 (Ex4), hepatocyte growth factor (HGF), insulin-like growth factor (IGF) and combinations thereof.

9. The method of claim 1 , wherein the retinoid is retinoic acid.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 15, 2016
From: D'AMOUR, KEVIN A.; BANG, ANNE; BAETGE, EMMANUEL E.
To: CYTHERA, INC.
Reel/Frame 039438/0430 →
CHANGE OF NAME Recorded Aug 15, 2016
From: CYTHERA, INC.
To: VIACYTE, INC.
Reel/Frame 039687/0851 →
Continuity (7)
Continuation 14072491 · Nov 5, 2013
Continuation 13275274 · Oct 17, 2011
Division 11681687 · Mar 2, 2007
Provisional Application 60852878 · Oct 18, 2006
Provisional Application 60833633 · Jul 26, 2006
Provisional Application 60778649 · Mar 2, 2006
Related Publication 20160355787A1 · Dec 8, 2016
Cited By (4)
US 12,227,765 US 12,264,337 US 12,371,665 US 12,385,013